EQRx (EQRXW) Stock Analysis

What EQRx does

EQRx, Inc. is a pharmaceutical firm dedicated to developing novel therapeutic agents. Its primary focus lies in creating treatments for oncological and immune-inflammatory disorders, with its operations primarily situated in the United States. The company's pipeline includes several key investigational drugs: Aumolertinib, an EGFR inhibitor designed for non-small cell lung cancer (NSCLC) patients with EGFR mutations; Sugemalimab, an anti-PD-L1 antibody targeting advanced (stage III and IV) NSCLC; Lerociclib, a CDK4/6 inhibitor for the treatment of HR+/HER2- breast cancer; and EQ176, an anti-PD-1 antibody currently under evaluation for liver cancer. EQRx has formed strategic alliances with companies like Exscientia and AbCellera Biologics Inc. The company was founded in 2020 and its corporate base is located in Cambridge, Massachusetts.

Key metrics

ETFs linked to EQRXW

Broad-market and Healthcare sector ETFs an investor holding EQRx is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EQRXW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for EQRx?

EQRx trades under the ticker EQRXW on NASDAQ.

Which exchange is EQRXW listed on?

EQRXW is listed on NASDAQ.

What sector does EQRx operate in?

EQRx is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EQRXW in a portfolio?

PortView shows EQRXW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.